This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

dulaglutide (Trulicity®)

Reference No. 866

Publication date:

Last review date:

Appraisal information

dulaglutide (Trulicity®) 0.75 mg solution for injection
dulaglutide (Trulicity®) 1.5 mg solution for injection

Company: Eli Lilly & Co Ltd
BNF category: Endocrine system
NMG meeting date: 13/04/2016
AWMSG meeting date: 18/05/2016
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1116
Ratification by Welsh Government: 10/06/2016

Current Progress

Ratification by
Welsh Government

AWMSG advice

Dulaglutide (Trulicity®) is recommended as an option for restricted use within NHS Wales. Dulaglutide (Trulicity®) should be restricted for use in the following subpopulation/circumstances within its licensed indication for the treatment of type 2 diabetes in adults to improve glycaemic control: After failure, intolerance or where there is a contraindication to, standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy. In combination with other glucose-lowering medicinal products but not including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control, in line with current NICE guidance. Dulaglutide (Trulicity®) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary